Contributions of the structural proteins of severe respiratory syndrome coronavirus to protective immunity

Ursula J. Buchholz, Alexander Bukreyev, Lijuan Yang, Elaine W. Lamirande, Brian R. Murphy, Kanta Subbarao, Peter L. Collins

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

We investigated the contributions of the structural proteins of severe acute respiratory syndrome (SARS) coronavirus (CoV) to protective immunity by expressing them individually and in combinations from a recombinant parainfluenza virus (PIV) type 3 vector called BHPIV3. This vector provided direct immunization of the respiratory tract, the major site of SARS transmission, replication, and disease. The BHPIV3/SARS recombinants were evaluated for immunogenicity and protective efficacy in hamsters, which support a high level of pulmonary SARS-CoV replication. A single intranasal administration of BHPIV3 expressing the SARS-CoV spike protein (S) induced a high titer of SARS-CoV-neutralizing serum antibodies, only 2-fold less than that induced by SARS-CoV infection. The expression of S with the two other putative virion envelope proteins, the matrix M and small envelope E proteins, did not augment the neutralizing antibody response. In absence of S, expression of M and E or the nucleocapsid protein N did not induce a detectable serum SARS-CoV-neutralizing antibody response. Immunization with BHPIV3 expressing S provided complete protection against SARS-CoV challenge in the lower respiratory tract and partial protection in the upper respiratory tract. This was augmented slightly by coexpression with M and E. Expression of M, E, or N in the absence of S did not confer detectable protection. These results identify S among the structural proteins as the only significant SARS-CoV neutralization antigen and protective antigen and show that a single mucosal immunization is highly protective in an experimental animal that supports efficient replication of SARS-CoV.

Original languageEnglish (US)
Pages (from-to)9804-9809
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume101
Issue number26
DOIs
StatePublished - Jun 29 2004
Externally publishedYes

Fingerprint

Severe Acute Respiratory Syndrome
Coronavirus
Immunity
Proteins
Neutralizing Antibodies
Respiratory System
Immunization
Antibody Formation
Coronavirus Spike Glycoproteins
Human parainfluenza virus 3
Coronavirus Infections
Nucleocapsid Proteins
Antigens
Intranasal Administration
Protein S
Serum
Cricetinae
Virion

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Contributions of the structural proteins of severe respiratory syndrome coronavirus to protective immunity. / Buchholz, Ursula J.; Bukreyev, Alexander; Yang, Lijuan; Lamirande, Elaine W.; Murphy, Brian R.; Subbarao, Kanta; Collins, Peter L.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, No. 26, 29.06.2004, p. 9804-9809.

Research output: Contribution to journalArticle

Buchholz, Ursula J. ; Bukreyev, Alexander ; Yang, Lijuan ; Lamirande, Elaine W. ; Murphy, Brian R. ; Subbarao, Kanta ; Collins, Peter L. / Contributions of the structural proteins of severe respiratory syndrome coronavirus to protective immunity. In: Proceedings of the National Academy of Sciences of the United States of America. 2004 ; Vol. 101, No. 26. pp. 9804-9809.
@article{8c52224a432a4255921eee96a8732239,
title = "Contributions of the structural proteins of severe respiratory syndrome coronavirus to protective immunity",
abstract = "We investigated the contributions of the structural proteins of severe acute respiratory syndrome (SARS) coronavirus (CoV) to protective immunity by expressing them individually and in combinations from a recombinant parainfluenza virus (PIV) type 3 vector called BHPIV3. This vector provided direct immunization of the respiratory tract, the major site of SARS transmission, replication, and disease. The BHPIV3/SARS recombinants were evaluated for immunogenicity and protective efficacy in hamsters, which support a high level of pulmonary SARS-CoV replication. A single intranasal administration of BHPIV3 expressing the SARS-CoV spike protein (S) induced a high titer of SARS-CoV-neutralizing serum antibodies, only 2-fold less than that induced by SARS-CoV infection. The expression of S with the two other putative virion envelope proteins, the matrix M and small envelope E proteins, did not augment the neutralizing antibody response. In absence of S, expression of M and E or the nucleocapsid protein N did not induce a detectable serum SARS-CoV-neutralizing antibody response. Immunization with BHPIV3 expressing S provided complete protection against SARS-CoV challenge in the lower respiratory tract and partial protection in the upper respiratory tract. This was augmented slightly by coexpression with M and E. Expression of M, E, or N in the absence of S did not confer detectable protection. These results identify S among the structural proteins as the only significant SARS-CoV neutralization antigen and protective antigen and show that a single mucosal immunization is highly protective in an experimental animal that supports efficient replication of SARS-CoV.",
author = "Buchholz, {Ursula J.} and Alexander Bukreyev and Lijuan Yang and Lamirande, {Elaine W.} and Murphy, {Brian R.} and Kanta Subbarao and Collins, {Peter L.}",
year = "2004",
month = "6",
day = "29",
doi = "10.1073/pnas.0403492101",
language = "English (US)",
volume = "101",
pages = "9804--9809",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "26",

}

TY - JOUR

T1 - Contributions of the structural proteins of severe respiratory syndrome coronavirus to protective immunity

AU - Buchholz, Ursula J.

AU - Bukreyev, Alexander

AU - Yang, Lijuan

AU - Lamirande, Elaine W.

AU - Murphy, Brian R.

AU - Subbarao, Kanta

AU - Collins, Peter L.

PY - 2004/6/29

Y1 - 2004/6/29

N2 - We investigated the contributions of the structural proteins of severe acute respiratory syndrome (SARS) coronavirus (CoV) to protective immunity by expressing them individually and in combinations from a recombinant parainfluenza virus (PIV) type 3 vector called BHPIV3. This vector provided direct immunization of the respiratory tract, the major site of SARS transmission, replication, and disease. The BHPIV3/SARS recombinants were evaluated for immunogenicity and protective efficacy in hamsters, which support a high level of pulmonary SARS-CoV replication. A single intranasal administration of BHPIV3 expressing the SARS-CoV spike protein (S) induced a high titer of SARS-CoV-neutralizing serum antibodies, only 2-fold less than that induced by SARS-CoV infection. The expression of S with the two other putative virion envelope proteins, the matrix M and small envelope E proteins, did not augment the neutralizing antibody response. In absence of S, expression of M and E or the nucleocapsid protein N did not induce a detectable serum SARS-CoV-neutralizing antibody response. Immunization with BHPIV3 expressing S provided complete protection against SARS-CoV challenge in the lower respiratory tract and partial protection in the upper respiratory tract. This was augmented slightly by coexpression with M and E. Expression of M, E, or N in the absence of S did not confer detectable protection. These results identify S among the structural proteins as the only significant SARS-CoV neutralization antigen and protective antigen and show that a single mucosal immunization is highly protective in an experimental animal that supports efficient replication of SARS-CoV.

AB - We investigated the contributions of the structural proteins of severe acute respiratory syndrome (SARS) coronavirus (CoV) to protective immunity by expressing them individually and in combinations from a recombinant parainfluenza virus (PIV) type 3 vector called BHPIV3. This vector provided direct immunization of the respiratory tract, the major site of SARS transmission, replication, and disease. The BHPIV3/SARS recombinants were evaluated for immunogenicity and protective efficacy in hamsters, which support a high level of pulmonary SARS-CoV replication. A single intranasal administration of BHPIV3 expressing the SARS-CoV spike protein (S) induced a high titer of SARS-CoV-neutralizing serum antibodies, only 2-fold less than that induced by SARS-CoV infection. The expression of S with the two other putative virion envelope proteins, the matrix M and small envelope E proteins, did not augment the neutralizing antibody response. In absence of S, expression of M and E or the nucleocapsid protein N did not induce a detectable serum SARS-CoV-neutralizing antibody response. Immunization with BHPIV3 expressing S provided complete protection against SARS-CoV challenge in the lower respiratory tract and partial protection in the upper respiratory tract. This was augmented slightly by coexpression with M and E. Expression of M, E, or N in the absence of S did not confer detectable protection. These results identify S among the structural proteins as the only significant SARS-CoV neutralization antigen and protective antigen and show that a single mucosal immunization is highly protective in an experimental animal that supports efficient replication of SARS-CoV.

UR - http://www.scopus.com/inward/record.url?scp=3042714194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042714194&partnerID=8YFLogxK

U2 - 10.1073/pnas.0403492101

DO - 10.1073/pnas.0403492101

M3 - Article

C2 - 15210961

AN - SCOPUS:3042714194

VL - 101

SP - 9804

EP - 9809

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 26

ER -